Eyenovia to feature commercial products, Optejet Dispenser at eyecare meetings

Eyenovia announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings. “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer. “With Mydcombi available for pre-surgical pupil dilation, clobetasol available for post-surgical pain and inflammation, and Avenova Antimicrobial Lid and Lash Solution used both pre- and post-surgery to reduce the number of pathogens that can lead to infection, we have evolved into the ‘partner of choice’ for leading ophthalmic and optometric practices and surgical institutions. These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device. We continue to lay a foundation from which we believe we can drive a meaningful acceleration in sales growth in 2025.” Eyenovia will feature an entire suite of commercial products – Mydcombi, clobetasol and Avenova – at the ASCRS Annual Meeting, which is being held April 5-8, 2024, in Boston. The Vison Source Exchange, which is being held April 10-13 in Orlando, is the country’s largest gathering of private practice optometrists with more than a thousand of the most successful ODs in the nation. Eyenovia will be on hand to demonstrate and sell Mydcombi.